Kathleen Sebelius Purchases 56,818 Shares of Humacyte (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius bought 56,818 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was bought at an average cost of $0.88 per share, with a total value of $49,999.84. Following the completion of the acquisition, the director owned 148,025 shares of the company’s stock, valued at $130,262. This represents a 62.30% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Humacyte Trading Up 11.2%

Shares of Humacyte stock opened at $1.02 on Friday. Humacyte, Inc. has a 12-month low of $0.55 and a 12-month high of $2.93. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. The stock has a market cap of $226.46 million, a PE ratio of -1.79 and a beta of 2.31. The company has a 50-day moving average of $0.83 and a two-hundred day moving average of $1.04.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $1.46 million. On average, research analysts anticipate that Humacyte, Inc. will post -0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Sei Investments Co. purchased a new position in shares of Humacyte during the 1st quarter worth approximately $56,000. R Squared Ltd increased its stake in shares of Humacyte by 140.5% during the 1st quarter. R Squared Ltd now owns 62,911 shares of the company’s stock worth $38,000 after purchasing an additional 36,758 shares in the last quarter. Private Advisor Group LLC increased its stake in shares of Humacyte by 48.3% during the 1st quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock worth $505,000 after purchasing an additional 271,222 shares in the last quarter. Wealth Effects LLC boosted its position in Humacyte by 33.6% during the first quarter. Wealth Effects LLC now owns 204,500 shares of the company’s stock worth $124,000 after acquiring an additional 51,433 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Humacyte by 841.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock worth $68,000 after acquiring an additional 62,931 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HUMA shares. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Tuesday, April 28th. Finally, BTIG Research dropped their price objective on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.